ArticleLupus science & medicine2025
Complete blood count-derived biomarkers as indicators of systemic lupus erythematosus activity: a cross-sectional comparative study.
Article in Lupus science & medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Peripheral Blood Neutrophil-to-Lymphocyte Ratio Combined With Fibrinogen-to-Albumin Ratio Assists in Identifying Systemic Lupus Erythematosus Activity and Lupus Nephritis.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2026Article
- Inflammatory-Hematological Profiles in Nasopharyngeal Carcinoma and Suspicious Adenoid Hypertrophy: An Exploratory Single-Center Study.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSLE is a chronic autoimmune disease with heterogeneous manifestations. This study evaluated the discriminative value of complete blood count-derived biomarkers, including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), eosinophil-to-lymphocyte ratio (ELR), basophil-to-lymphocyte ratio (BLR), mean platelet volume and red cell distribution width (RDW), in identifying lupus flares.
methodsThis cross-sectional study was conducted over 10 years in the internal medicine department of Sahloul Hospital. SLE patients were classified by disease activity using Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K): flare (SLEDAI-2K >6) or remission (SLEDAI-2K ≤6). A matched group of healthy controls was included. Comparisons were made between flare/remission and flare/controls. Discriminative performance of biomarkers was evaluated using receiver operating characteristic analysis, with sensitivity (Se), specificity (Sp) and area under the curve (AUC) determined for the optimal cut-off values.
resultsThe study included 83 SLE patients (40 flares, 43 remission) and 85 controls, median age of 32 years and a sex ratio of 0.16. Compared with remission, flares had significantly higher NLR and RDW and lower ELR. The most discriminative biomarkers were RDW (AUC=0.708, cutoff ≥14.65, Se =75.9%, Sp =60.6%), NLR (AUC =0.636, cutoff ≥2.63, Se =72.4%, Sp =51.5%) and ELR (AUC =0.647, cutoff ≤0.0076, Se =74.4%, Sp =65%). Compared with controls, flares showed higher NLR, PLR, MLR, RDW and lower ELR and BLR. Best performances were RDW (AUC =0.864, cutoff ≥13.85, Se =89.7%, Sp =75.3%), NLR (AUC =0.822, cutoff ≥2.28, Se =79.3%, Sp =76.5%) and ELR (AUC =0.775, cutoff ≤0.029, Se =87.1%, Sp =70.3%). SLEDAI-2K correlated positively with NLR (r =0.228), PLR (r =0.238), RDW (r =0.303) and negatively with ELR (r =-0.317).
conclusionsThese biomarkers may serve as simple, accessible and cost-effective tools for detecting lupus flares, particularly in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.